A review found 20 studies of a copper peptide, only two of them in people

One molecule sits behind most of the copper peptide products in skin care: glycyl-L-histidyl-L-lysine joined to a copper ion, written GHK-Cu. It has a large laboratory literature and a very small human one. A systematic review published in Aesthetic Surgery Journal in August 2026 counted both [1].

What the review counted

The search ran across PubMed, Embase and Cochrane CENTRAL from the first record each database holds through March 2026, following PRISMA, a published checklist that sets out how a systematic review should be run and reported. Twenty studies met the criteria. Eighteen were preclinical, meaning done in cells or in animals. Two were randomised controlled trials, in which people are assigned by chance to the thing being tested or to a comparison [1].

The preclinical studies agreed with each other. Across them the molecule increased production of type I collagen and of glycosaminoglycans, both structural material in skin; changed the activity of metalloproteinases, the enzymes that break that material down; encouraged new blood vessels to form; and lowered two inflammation signals, TGF beta and IL-6. The review also reports that microneedle and liposome delivery moved considerably more of it through skin than plain application did [1].

Nevertheless, the findings reported across studies were constrained by methodological variability and a limited number of well-designed clinical trials.

The Regenerative Potential of GHK-Cu in Aesthetic Medicine, Aesthetic Surgery Journal, August 2026 [1]

The randomised human record

Searching the indexed literature for randomised studies of this molecule in people returns two.

The older is from 1992, in the Journal of Vascular Surgery, and it is about wounds rather than wrinkles. Eighty six evaluable patients with venous leg ulcers, the slow healing open sores that follow poor blood return from the legs, were randomly assigned, with the assessors kept unaware of who got what, to a 0.4 percent copper tripeptide cream, a 1 percent silver sulfadiazine cream, or the inactive vehicle alone. The silver cream shrank ulcers more than either of the others. Between the copper peptide cream and the inert vehicle, the trial reports no difference [3].

The other is from 2006, in Archives of Facial Plastic Surgery, in skin resurfaced with a carbon dioxide laser. Thirteen patients completed it. They were randomised to an aftercare routine with or without the copper peptide, and redness was measured both by software and by evaluators kept unaware of the assignment. On redness the groups did not differ. On wrinkles and overall skin quality at 12 weeks every patient improved, and again the groups did not differ. One measurement did separate them: on a questionnaire the patients completed themselves, the copper peptide group rated their skin quality higher, at P equals 0.04 [2].

Thirteen people is a very small trial, and the single measurement that separated the groups is the one the patients scored themselves. That is the weakest kind of evidence in a study of appearance, and it is the finding most often repeated [2].

Where the new work is going

Research on this molecule since 2024 is busy and almost entirely preclinical. A 2026 paper in Biogerontology fed it to Caenorhabditis elegans, a roundworm about a millimetre long that is a standard laboratory model for aging, and reported a longer lifespan along with better movement, better resistance to heat and to oxidative stress, and less build up of the pigment lipofuscin. The authors trace the effect to mitochondrial function and to two stress response pathways called DAF-16 and SKN-1, and describe their work as the first mechanistic evidence that the molecule delays aging in that animal [4].

A worm is a long way from a face. The value of a study like that is the mechanism it maps, which is what tells a later human trial where to look. It is not evidence about skin, and the paper does not present it as such [4].

What a regulator has said

The United States Food and Drug Administration keeps a list of raw ingredients that facilities mixing medicines to order may want to use, and a category inside it for ingredients the agency judges may present significant safety risks. The injectable form of this molecule was placed in that category on 29 September 2023. The reason recorded is that injectable preparations containing it may carry a risk of immunogenicity, meaning the immune system reacting to the preparation itself, because the peptide can clump together and because related impurities may be present, and that there are limited data in humans to inform safety considerations [5].

That is not a finding of harm, and it says nothing about creams, which reach the market under a different part of the law. It is a statement that the agency does not have the human data it would want before an injectable version is mixed for patients [5].

What would settle it

The review's own recommendation is larger controlled trials using standardised preparations, amounts and delivery methods. Until such a trial exists, the accurate description of this record is a consistent laboratory case that has been tested against a comparison in people twice, in 86 patients and in 13, and that separated from it neither time on any measurement an instrument or a blinded grader took [1][2][3].